Leukemia inhibitory factor plays an essential role in the properties of K-Ras-induced pancreatic cancer stem cells, and may serve as a novel therapeutic target to eradicate pancreatic cancers with K-Ras activations.
Patients with pancreatic cancer and two variant alleles of a single-nucleotide polymorphism (SNP) in VDR, the gene coding for the vitamin D receptor, have higher rates of overall survival (OS).
Metformin was found to target human pancreatic cancer stem cells in preclinical mouse models.
A highly accurate, blood-based diagnostic panel comprising 40 individual serum biomarkers of pancreatic adenocarcinoma would provide high specificity while allowing for heterogeneity among patients and tumor characteristics.
In patients with locally advanced pancreatic cancer, radiotherapy with concurrent erlotinib, bevacizumab, and capecitabine is safe and tolerable, with “promising” overall survival rates and a high rate of resectability at higher dose levels.
Exposure to high ultraviolet radiation (UVR) at an individual’s birth location confers a lower risk of pancreatic cancer.
Sequential delivery of the new targeted therapy vismodegib (GDC-0449; Erivedge) as monotherapy followed by combination treatment with gemcitabine provides clinical benefit to a subset of patients with metastatic pancreatic cancer.
The multifunctional cell membrane protein RLIP76 represents a mechanistically significant target for developing effective interventions for pancreatic cancers resistant to chemotherapy and radiation.
Long regarded as the most lethal form of cancer, and a leading cause of death from cancer worldwide, pancreatic cancer remains largely elusive to early detection and warning symptoms.
Radiographic downstaging rare even after neoadjuvant therapy in pancreatic cancer patients.
